Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   18/12/2025
51,95 USD (+0,29%)
(+0,29%)   18/12/2025

11 november 2025 · BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England · Persbericht

29 oktober 2025 · FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria · Persbericht

27 oktober 2025 · BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update · Persbericht

22 oktober 2025 · BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET · Persbericht

8 september 2025 · BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting · Persbericht

6 september 2025 · BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism · Persbericht

27 augustus 2025 · BioMarin to Participate in Upcoming Investor Conferences · Persbericht

4 augustus 2025 · BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS · Persbericht

1 augustus 2025 · BioMarin Announces Appointment of Ian T. Clark to Board of Directors · Persbericht

22 juli 2025 · BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET · Persbericht

1 juli 2025 · BioMarin Announces Completion of Acquisition of Inozyme · Persbericht

24 juni 2025 · BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress · Persbericht

16 mei 2025 · BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma · Persbericht

12 mei 2025 · BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings · Persbericht

1 mei 2025 · BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance · Persbericht

17 april 2025 · BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET · Persbericht

2 april 2025 · BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria · Persbericht

20 maart 2025 · BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

4 september 2024 · BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance · Persbericht

4 september 2024 · BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time · Persbericht

Mijn selecties